Bone marrow-derived CD13+ cells sustain tumor progression: A potential non-malignant target for anticancer therapy
MetadataShow full item record
CitationDondossola, Eleonora, Angelo Corti, Richard L Sidman, Wadih Arap, and Renata Pasqualini. 2014. “Bone marrow-derived CD13+ cells sustain tumor progression: A potential non-malignant target for anticancer therapy.” Oncoimmunology 3 (1): e27716. doi:10.4161/onci.27716. http://dx.doi.org/10.4161/onci.27716.
AbstractNon-malignant cells found within neoplastic lesions express alanyl (membrane) aminopeptidase (ANPEP, best known as CD13), and CD13-null mice exhibit limited tumor growth and angiogenesis. We have recently demonstrated that a subset of bone marrow-derived CD11b+CD13+ myeloid cells accumulate within neoplastic lesions in several murine models of transplantable cancer to promote angiogenesis. If these findings were confirmed in clinical settings, CD11b+CD13+ myeloid cells could become a non-malignant target for the development of novel anticancer regimens.
Citable link to this pagehttp://nrs.harvard.edu/urn-3:HUL.InstRepos:13890756
- HMS Scholarly Articles